Host: The Japanese Pharmacological Society, The Japanese Society of Clinical Pharmacology
Name : WCP2018 (18th World Congress of Basic and Clinical Pharmacology)
Location : Kyoto
Date : July 01, 2018 - July 06, 2018
Precision medicine requires treatment individualization taking into account not only patient and tumor factors, but also intra-tumor heterogeneity and tumor evolution through time. We propose that the next generation of personalized precision drugs will come from the development of physiologically relevant "real- or accelerated-time" models of individual patient-specific tumors, that mimic tumor pathology, and progression. Importantly, such models could serve as a powerful personalized screening platform for clinical genomics-informed predictions for genetic and therapeutic vulnerabilities that can subsequently be used to provide testable therapeutic and diagnostic modalities in the clinic. With that in mind, we have developed a bank of primary patient-derived xenograft (PDx), and microtumor/primary cell line (PDmT/PDC) models of oral squamous cell carcinomas (OSCCs), and colorectal cancers (CRCs) that are amenable to high-throughput and high-content screens (HTS/HCS). Using comprehensive tumor profiling studies, and single cell transcriptomics in conjunction with image-based phenotypic screens, we are beginning to uncover novel therapeutic vulnerabilities, as well as key driver genes/pathways and their function that may regulate cancer metastasis and evolution of drug resistance, the two most common causes of cancer-related mortality.
